P/E Ratio

AstraZeneca’s current P/E ratio of 27.0x means investors are paying $27.00 for every $1.00 of the company’s earnings per share — a common valuation measure that compares stock price to profitability.

This sits above the sector median of 24.6x, placing the stock at the 59th percentile among healthcare peers, indicating a slightly higher valuation than most. No historical trend data is available: the year-over-year change, quarter-over-quarter change, and eight-quarter trend direction are all listed as N/A. The absence of any trend information means investors cannot assess whether the P/E is rising or falling, leaving the current level as the only signal. A valuation above the sector median without trend context introduces no clear risk or opportunity — the stock is priced above average, but without momentum data, the implication is neutral. This metric supports the overall NEUTRAL verdict: the P/E is neither extremely expensive nor cheap, and the lack of trend removes any directional bias.

Frequently Asked Questions

Closest Sector Peers